Dermaseptin S4 (1-22)

General Information


DRACP ID  DRACP02904

Peptide Name   Dermaseptin S4 (1-22)

Sequence  ALWMTLLKKVLKAAAKAALNAV

Sequence Length  22

UniProt ID  P80280 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
SW620 Colon adenocarcinoma Carcinoma 66.21±20.07% Cytotoxicity=256 µg/ml MTT assay 3h 1

Hemolytic Activity  Human erythrocytes: 80±1.12% Hemolysis=256 µg/ml

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02904

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C109H190N28O25S

Absent amino acids  CDEFGHIPQRSY

Common amino acids  A

Mass  269974

Pl  11.28

Basic residues  4

Acidic residues  0

Hydrophobic residues  15

Net charge  4

Boman Index  1862

Hydrophobicity  96.36

Aliphatic Index  146.82

Half Life 
  Mammalian: 4.4 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  5500

Absorbance 280nm  261.9

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 33774792

Title  Evaluating the effect of dermaseptin S4 and its derivatives on multidrug-resistant bacterial strains and on the colon cancer cell line SW620

Doi 10.1007/s11356-021-13683-2 Abstract

Year  2021

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_18032

DRACP is developed by Dr.Zheng's team.